Galapagos starts Phase I for CF candidate GLPG3221

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) started a Phase I trial to evaluate safety and pharmacokinetics of cystic fibrosis (CF) candidate GLPG3221 in healthy volunteers. The trial start triggered a $10 million milestone payment to Galapagos from AbbVie Inc. (NYSE:ABBV). The companies partnered in 2013 to develop and commercialize oral potentiators and correctors of mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene including G551D and delta F508 mutations (see BioCentury, Sept. 30, 2013)...